Episode Details

Noom CEO Geoff Cook returns to Hims House to discuss the company's acquisition of Tailor Made Compounding, a 503A pharmacy in 46 states, and what it signals about Noom's expansion beyond weight loss into healthy aging. Cook explains why vertical integration matters now, from supply chain control to faster R&D on peptides, as 14 peptides may soon return to being legal to compound. He shares his outlook on compounded GLP-1 regulation, branded oral offerings like the Wegovy pill, and why DTC-pharma partnerships are set to accelerate. The conversation digs into peptide market sizing, competition dynamics, and Noom's plan to expand at-home biomarker testing past 30 markers. Cook also makes the case for Noom's moat in engagement and behavior change and shares his personal BPC-157 recovery story.

00:00 - Why pharma needs DTC platforms

01:12 - Sponsor: Mochi Health

03:03 - Noom's 90% revenue growth

05:01 - Why Noom bought Tailor Made Pharmacy (503A)

07:29 - The case for vertical integration

08:56 - Compounded GLP-1s aren't going anywhere

16:48 - The Hims-Novo deal

19:08 - Noom's pitch to next-gen pharma

24:24 - Peptide market sizing

25:33 - Why GLP-1 users will buy peptides first

27:22 - Ten million potential peptide patients 👀

30:09 - When will legalization happen?

31:09 - Tracking the FDA green list

34:26 - Who wins when peptides go legal?

37:58 - Why Noom won't rush peptide launch

39:33 - Geoff's BPC-157 ski injury recovery

46:42 - Expanding at-home labs past 30 biomarkers

52:47 - Noom IPO coming?!

Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.